Open AccessSevere headache in primary Sjögren’s syndrome treated with intrathecal rituximab
Author(s) -
Tjensvoll Anne Bolette,
Lauvsnes Maria Boge,
Norheim Katrine Brekke,
Omdal Roald
Publication year - 2019
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.1987
Subject(s) - medicine , triptans , rituximab , intrathecal , pathogenesis , primary headache , immunology , migraine , anesthesia , antibody
Key Clinical Message A severe and persistent migrainous headache in a patient with primary Sjøgren's syndrome unresponsive to treatment with immunosuppressive drugs, triptans, opioids, and NSAIDs, responded successfully to intrathecal B‐cell depletion with rituximab. We hypothesize that brain‐resident autoreactive B cells were involved in headache pathogenesis and were eliminated by this procedure.